Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039516 | 0.86 | ADRB2 (0.37) | CYP2A6ADRB2ADRB1PDCD1CD274 | |
| SCHEMBL3262485 | 0.78 | CASP3 (0.36) | KMT2AHTTALDH1A1 | |
| SCHEMBL45454 | 0.75 | CYP2C19 (0.33) | ALDH1A1 | |
| SCHEMBL14809990 | 0.73 | PDCD1 (0.35) | CYP2A6ADRB2PDCD1CD274DPP4 | |
| SCHEMBL7555105 | 0.67 | TSHR (0.36) | KMT2AHTTALDH1A1 | |
| SCHEMBL23390709 | 0.66 | — | — | |
| SCHEMBL624569 | 0.65 | CYP3A4 (0.39) | KMT2AHTTALDH1A1HPGD | |
| SCHEMBL10029671 | 0.65 | CYP2A6 (0.52) | CYP2A6PDCD1CD274DPP4ALDH1A1 | |
| Bromide SCHEMBL7610464 | 0.64 | CYP3A4 (0.38) | KMT2AALDH1A1HPGD | |
| SCHEMBL15260401 | 0.63 | ALDH1A1 (0.41) | CYP2A6PDCD1CD274DPP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198471-B2 | 2, 2′-bis (dialkylphosphino) biphenyl compound, production method thereof, and metal complex comprising the compound as ligand | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100234626-A1 | 2, 2'-BIS (DIALKYLPHOSPHINO) BIPHENYL COMPOUND, PRODUCTION METHOD THEREOF, AND METAL COMPLEX COMPRISING THE COMPOUND AS LIGAND | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234626-A1 | 2, 2'-BIS (DIALKYLPHOSPHINO) BIPHENYL COMPOUND, PRODUCTION METHOD THEREOF, AND METAL COMPLEX COMPRISING THE COMPOUND AS LIGAND | BMPR1A, ADORA1, BMPR1B | CYP2A6 615/4885ADRB2 1256/4885ADRB1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.